MonTa Biosciences is a Clinical Stage Biotech Company with a vision to develop better cancer treatment to patients in need. Our lead candidate MBS8 is in phase I clinical trial with treatment of currently more then 45 patients at clinical sites in Denmark, Belgium and Spain.

MBS8 is a novel Lipid Nano Particle formulation with several unique selling points:

  • Due to the Lipid Nano Particle (LNP) we have increased the Therapeutic Index by more than 20 fold
  • Immune stimulating LNPs are engineered to reduce systemic cytokine production with a favourable safety profile
  • Administration by IV infusion is a major advantage for doctors and patients to minimize complications
  • MBS8 is an LNP incorporating a small molecule TLR7 NCE agonist
  • MBS8 show superior anti-tumor activity in preclinical models compared to many approved treatments
  • Synergy with Immune Checkpoint Inhibitors, radiotherapy and chemotherapy with complete remission in preclinical models


MonTa Biosciences announces completion of patient cohort in our phase I clinical trial

We are pleased to announce the successful completion of the current dose level study involving [...]

Read more
Come and meet us and discuss business and partnering at Bio International in San Diego June 3 to 6th

MonTa Biosciences CEO, Simon S Jensen will be attending Bio International in San Diego in [...]

Read more
Meet us in San Diego for SITC November 3-5, 2023

MonTa Biosciences will be joining the Society for Immunotherapy and Cancer Therapy (SITC) in San [...]

Read more
MonTa Biosciences treat the first patients with the highest dose of MBS8 ever

In the last week of September 2023 we dosed patient number 31 and 32 with [...]

Read more